Structured around addressing the gap between when a potentially useful new drug moves from post-discovery and animal eficacy to the clinical phase, Lamassu Pharma personnel are using their expertise in early transisitonal research to address bringing potential products to Phase I/II clincal trial far faster and intimely manner. Begining with a novel, small molecule therapy that was developed by leading players at the Mayo Clinic and that has shown profound efficacy completely to mitigate mortality and morbidity associated with severe acute pancreatitis in animal models, the first drug of focus is a novel small molecule therapy for acute pancreatitis. In the US annually, acute pancreatitis is a leading cause of emergency department visits and gastrointestinal admissions with over 330,000 hospital admissions per year having a significant mortality and long term complications. Expediting the process to in-use condition could enable the company's therapeutics to mitigate the mortality and morbidity associated with severe acute pancreatitis, enabling physicians to save the lives of patients afflicted with this disease with better medical outcomes.
